CLINICAL TRIALS PROFILE FOR INTEGRILIN
✉ Email this page to a colleague
All Clinical Trials for INTEGRILIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00089895 ↗ | EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) | Completed | Duke Clinical Research Institute | Phase 3 | 2004-11-01 | The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide). |
| NCT00089895 ↗ | EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-11-01 | The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide). |
| NCT00250991 ↗ | Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1/Phase 2 | 2003-07-01 | The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke. |
| NCT00250991 ↗ | Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial | Completed | University of Cincinnati | Phase 1/Phase 2 | 2003-07-01 | The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke. |
| NCT00638976 ↗ | INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial | Completed | Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS | Phase 3 | 2007-11-01 | Randomized, blind controlled, Multicenter, spontaneous, prospective trial, roughly 20 enrolling centers in Italy, placebo and active drug supply given by GlaxoSmithKline (GSK). |
| NCT00638976 ↗ | INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial | Completed | Fondazione Mediolanum per Attività e Ricerche Cardiovascolari Onlus | Phase 3 | 2007-11-01 | Randomized, blind controlled, Multicenter, spontaneous, prospective trial, roughly 20 enrolling centers in Italy, placebo and active drug supply given by GlaxoSmithKline (GSK). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for INTEGRILIN
Condition Name
Clinical Trial Locations for INTEGRILIN
Trials by Country
Clinical Trial Progress for INTEGRILIN
Clinical Trial Phase
Clinical Trial Sponsors for INTEGRILIN
Sponsor Name
